Spun out of Tübingen, Justus Liebig University Gießen and Münster, Atriva Therapeutics has raised an initial $1.4m to progress next-generation antiviral drugs for conditions including influenza.
Atriva Therapeutics, a Germany-based antiviral therapy spinout from the universities of Tübingen, Justus Liebig Gießen and Münster, has raised €1.3m ($1.4m) in an initial series A tranche co-led by public-private partnership High-Tech Gründerfonds and investment firm Meneldor.
The round also features unnamed members of Atriva’s founding and management team.
Founded in 2015, Atriva is working on next-generation antiviral drugs to combat respiratory viral infections such as influenza, in the hope of counteracting flu strains that are becoming progressively…
